NSE ScannerPharmaceuticals · Pharmaceuticals: Major · NSE: ANUHPHR · data 2026-11-01
Anuh Pharma Limited
In plain words
Price: 12.3% below its 52-week high of ₹99.5.
Delivery: 54.8% of traded shares were kept for delivery over the last 10 sessions, against 59.0% over the last 60.
A description of the data, not a recommendation.
Key figures
Growth
| Revenue (last 12 months) | ₹779 cr |
| Net profit (last 12 months) | ₹44 cr |
| Sales growth, 3 years (yearly) | 13.5% |
| Profit growth, 3 years (yearly) | 4.3% |
At a glance
P/E 15.7, dividend yield 1.7%. Price relative to earnings and book value (low is cheaper, not better).
ROE 12.1%, ROCE 17.0%, operating margin 6.9%: how much profit it earns on the money it uses.
Debt/equity 0.00, Profit growth 4.3% and sales growth 13.5% a year over 3 years.
Ratings use fixed thresholds on the latest reported figures. They describe the numbers and are not a recommendation.
Strengths and limitations
- Virtually debt-free (debt/equity 0.1 or less).
None flagged by these rules.
Picked automatically from the latest reported figures with fixed rules; check the company's filings before relying on them.
Smart-money activity
5/100 · Weak over the last ~60 sessions, data 2026-10-30
- Delivery vs usual 0/30: Delivery 45.7% over the last 20 sessions vs 49.1% in the 40 before (0.93x); shares delivered per day 0.56x usual; 0 delivery-spike days (3x usual shares delivered, 40%+ delivery) in the last 20 sessions.
- Bulk/block deals 0/20: No bulk or block deals in the last 90 days.
- Insider / SAST buys 0/15: No insider buy or SAST acquisition filings in the last 90 days. Insider sells are not collected by the site, so only buy filings count.
- Mutual fund holding 0/15: No mutual fund scheme lists this stock. Latest monthly portfolios only (top 60 holdings per scheme); month-on-month change is not stored.
- Accumulation evidence 0/15: No accumulation evidence row (only saved-scan stocks have one; 0 points).
- Promoter pledges 5/5: No promoter pledge filings in 90 days.
A description of recorded activity (delivery, deals, insider buys, fund holding, pledges), not a recommendation. Today's most active stocks.
Story so far
● Dividend ● Bonus
- 5 Aug 26Dividend Dividend ₹1.5 (ex-date) -1.3% next session
- 14 Aug 25Dividend Dividend ₹1.5 (ex-date) -1.5% next session
- 15 Jul 25Bonus Bonus 1:1 (ex-date) -1.4% next session
From official exchange filings and NSE data. How the price moved after an event describes the past, not what comes next.
Common questions
Is Anuh Pharma Limited debt-free?
Its latest reported debt-to-equity ratio is 0, so it carries little or no borrowing on the balance sheet.
What is Anuh Pharma Limited's P/E ratio?
About 15.7, based on the last 12 months' earnings and a price of ₹87.31 (data 2026-11-01).
What is the 52-week high and low of Anuh Pharma Limited?
The 52-week high is ₹99.5 and the 52-week low is ₹67.
Compared with similar companies
| Company | Price | Market cap | P/E | P/B | ROE | ROCE | Debt/eq. | 1-yr return |
|---|---|---|---|---|---|---|---|---|
| Anuh Pharma Limited | ₹87.31 | ₹873 cr | 15.7 | — | 12.1% | 17% | 0 | -1.1% |
| Lincoln Pharmaceuticals Ltd | ₹499.3 | ₹1,005 cr | 10.4 | — | 12.3% | 10.9% | 0.01 | -5.8% |
| Remus Pharmaceuticals Ltd. | ₹843.35 | ₹994 cr | 26.9 | 2.8 | 12.2% | 14.7% | 0.08 | +27.8% |
| Sudarshan Pharma Industries Ltd | ₹36.42 | ₹895 cr | 31.1 | 4.7 | 16.3% | 28.8% | 1.84 | +7.7% |
| Themis Medicare Limited | ₹94.83 | ₹875 cr | 21.9 | — | 0.3% | -2.3% | 0.25 | -24.0% |
| Shree Ganesh Remedies Ltd. | ₹617.25 | ₹792 cr | 51.3 | — | 11.5% | 14.4% | 0.19 | +24.7% |
Compare ANUHPHR with LINCOLN in detail →
The full analysis has the price chart, every quarterly result with YoY/QoQ growth, the balance sheet and cash flow with an accounting red-flag check, shareholding quarter by quarter with big investors, news, filings and bulk/block deals.
Open ANUHPHR in NSE Scanner →